Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | TACR2 | P21452 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27563659 | 0.90 | TDP1 (0.57) | TDP1L3MBTL1PTGS2CYP3A4KDM4E | |
| SCHEMBL27733869 | 0.87 | TDP1 (0.59) | TDP1L3MBTL1PTGS2CYP3A4KDM4E | |
| Hydrochloric Acid SCHEMBL28015977 | 0.85 | TDP1 (0.57) | TDP1L3MBTL1PTGS2CYP3A4KDM4E | |
| SCHEMBL19909258 | 0.82 | TDP1 (0.50) | TDP1L3MBTL1PTGS2CYP3A4KDM4E | |
| SCHEMBL20937692 | 0.82 | TDP1 (0.50) | TDP1L3MBTL1PTGS2CYP3A4KDM4E | |
| SCHEMBL19909082 | 0.82 | TDP1 (0.50) | TDP1L3MBTL1PTGS2CYP3A4KDM4E | |
| SCHEMBL20467132 | 0.81 | TDP1 (0.49) | TDP1L3MBTL1PTGS2CYP3A4KDM4E | |
| SCHEMBL20937651 | 0.81 | TDP1 (0.49) | TDP1L3MBTL1PTGS2CYP3A4KDM4E | |
| SCHEMBL511501 | 0.81 | TDP1 (0.49) | TDP1L3MBTL1PTGS2CYP3A4KDM4E | |
| SCHEMBL21230532 | 0.81 | TDP1 (0.49) | TDP1L3MBTL1PTGS2CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2390241-B1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-10-01 | — | — | EP | disclosed |
| US-8598349-B2 | Method for manufacturing conjugated aromatic compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-12-03 | — | — | US | disclosed |
| US-8293905-B2 | Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-10-23 | — | — | US | disclosed |
| US-8088883-B2 | Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| EP-2390241-A1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110275859-A1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-11-10 | — | — | US | disclosed |
| US-20110256790-A1 | THERMAL INSULATION CONTAINING SUPPLEMENTAL INFRARED RADIATION ABSORBING MATERIAL | SAINT-GOBAIN ISOVER (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-20100292481-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-11-18 | — | — | US | disclosed |
| EP-2233459-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-2172470-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275859-A1 | METHOD FOR MANUFACTURING CONJUGATED AROMATIC COMPOUND | C9, H1-10, CYP1A1 | TDP1 4003/4885L3MBTL1 602/4885PTGS2 4421/4885 |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | TDP1 3931/4885L3MBTL1 2833/4885PTGS2 4058/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | TDP1 4012/4885L3MBTL1 2253/4885PTGS2 4073/4885 |
| US-20100292481-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | TYR, PAH, AHR | TDP1 4605/4885L3MBTL1 3673/4885PTGS2 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.